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Abstract
Objective: Classic features of type 1 and type 2 diabetes may not apply in Asian Americans, due to shared absence of
common HLA DR-DQ genotype, low prevalence of positive anti-islet antibodies and low BMI in both types of diabetes. Our
objective was to characterize diabetic phenotypes in Asian Americans by clamp and clinical features.
Materials/Methods: This was a cross-sectional study conducted in a referral center. Thirty East young Asian American adult
volunteers (27.665.5 years) with type 1, type 2 diabetes or controls underwent hyperinsulinemic euglycemic clamp to
assess insulin resistance and DEXA to assess adiposity.
Results: Gender, BMI, waist/hip ratio, leptin, LDL, anti-GAD, anti-IA2 antibodies and C-reactive protein were similar among
three groups. Serum C-peptide, adiponectin, free fatty acid, HDL concentrations and truncal fat by DEXA, were different
between diabetic groups. Glucose disposal rate by clamp was lowest in type 2 diabetes, followed by type 1 diabetes and
controls (5.4362.70, 7.6262.59, 8.6162.37 mg/min/kg, respectively, p=0.001). Free fatty acid concentration universally
plummeted during steady state of the clamp procedure regardless of diabetes types in all three groups. Adipocyte fatty acid
binding protein in the entire cohort (r=20.625, p=0.04) and controls (r=20.869, p=0.046) correlated best with insulin
resistance, independent of BMI.
Conclusions: Type 2 diabetes in Asian Americans was associated with insulin resistance despite having low BMI as type 1
diabetes, suggesting a potential role for targeting insulin resistance apart from weight loss. Adipocyte fatty acid binding
protein, strongly associated with insulin resistance, independent of adiposity in the young Asian American population, may
potentially serve as a biomarker to identify at-risk individuals. Larger studies are needed to confirm this finding.
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Introduction
The prevalence of diabetes among developed Asian countries is
higher than countries in Europe or North America [1]. This is
consistent with Asian Americans (AA) experiencing a higher
prevalence of diabetes than Caucasians in the United States. In
1983, diabetes prevalence was approximately 20% in second-
generation Japanese American men 45–74 years old, compared to
12% Caucasian American men of comparable age [2]. In 2004,
16% of Asian American adults in New York City had diabetes and
nearly 45% had either diabetes or pre-diabetes [3], providing
more recent evidence that diabetes has become a major public
health challenge in the AA community. Since it has been observed
that there are multiple clinical and anthropometric features of
diabetes that are different between Asians and other ethnic groups,
it is not clear whether known clinical characteristics that define
type 1 from type 2 diabetes in the Caucasian population would be
applicable to Asians or AA. Characterizing the features of different
diabetic types in AA sheds important insight into the pathophys-
iology of diabetes and is crucial for clinicians to provide more
tailored and effective care in the diagnosis and treatment of
diabetes for this population.
Asians living in the Western Pacific region have the world’s
lowest prevalence of type 1 diabetes [1]. Uniquely, positivity of
auto-antibodies to islet cell antigens is only found in a minority of
the newly diagnosed Asians with type 1 diabetes [4], limiting the
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Furthermore, specific HLA DR and DQ genotype typically
associated with type 1 diabetes is not common in this population
[5]. Further diagnostic ambiguity arises from findings that Asians
and AA with type 2 diabetes present with a lower and often
normal BMI [6] and have younger onset of disease [7], as often
found in type 1 diabetes. These unusual characteristics of diabetes
in Asians not only render the differentiation of diabetic types
particularly difficult in clinical setting especially in younger adults
but also suggest that there may be endogenous factors that are
different with regard to insulin resistance (IR) in Asians and AA.
Final diagnosis often results from clinical observation for
ketoacidosis, status of insulin requirement, aided by c-peptide
concentration under appropriate clinical situations.
Studies using imaging techniques like DEXA and CT scan have
shown that Asian Americans have a higher percentage of visceral
fat relative to BMI [8] compared to Caucasians. Even with lower
BMIs, IR may be more severe in some of the Asian American
populations. Using hyperinsulinemic euglycemic clamp (HEC) in
healthy and normal weight individuals matched for BMI, Asian
Indian living in the U.S. may be more insulin resistant than
Caucasians [9]. However, within the Asian group, it is unclear if
IR is different across type 1, type 2 diabetes and controls, given
that individuals from all of these groups may all look phenotyp-
ically lean. This question has important clinical implications to the
Asian and AA population because the typical anthropometric
parameters such as BMI and body weight do not accurately reflect
degrees of IR and the associated risks for metabolic diseases [10].
If IR is found to be associated with either type of diabetes, it would
be important to determine the impact of addressing IR
independent of weight loss as advising weight loss may not be
appropriate for those who already have normal weight.
Inflammatory and endocrine markers, such as CRP, and other
adipose cytokines have been linked to IR although many of these
assays generate high degree of variability in the test results and are
more suitable for large epidemiologic studies. More recently,
retinol binding protein-4 (RBP-4), produced by the adipocytes and
liver, has been shown to correlate with insulin resistance in
Chinese [11,12]. In addition, another adipokine, A-FABP has
been shown to correlate with HOMA-IR in a Chinese population
[13,14] but has not been correlated with the gold standard
measurement of IR like HEC.
Given these unusual pathophysiologic features and diagnostic
ambiguity of diabetic types, in this pilot study, we set out to
characterize clinical phenotype in AA with type 1, type 2 diabetes
and healthy controls and conducted a direct comparative analysis
of IR by HEC and contrasted results to conventional and novel
biomarkers for IR.
Materials and Methods
Ethics Statement
The Institutional Review Board at Joslin Diabetes Center
approved this study. Written informed consent was obtained from
all participants and all investigation was conducted according to
the principles expressed in the Declaration of Helsinki.
The AA subjects in this study included volunteers with type 1
and 2 volunteers, according to the diagnoses given to them by their
health care providers, and healthy controls between 18–40 years of
age. All participants were of East Asian descendents only (Chinese,
Japanese, Korean). Exclusion criteria included history of symp-
tomatic coronary artery disease, peripheral vascular disease,
hypertension, hypertriglyceridemia (.500 mg/dl), microalbumin-
uria, active smoking, daily aspirin, ACE inhibitors, thiazolidine-
dione, supplementation of vitamin C or E beyond the recom-
mended daily allowance, blood transfusion in the previous three
months and pregnant/nursing females. Healthy controls did not
have a personal or family history of diabetes in their first-degree
relatives. Subjects who fulfilled demographic and diagnostic
criteria were identified via our clinic’s patient database and
recruited from community health centers, college campuses, and
fliers.
Subjects underwent phlebotomy, anthropometric measure-
ments, DEXA to determine adiposity and HEC to determine
insulin sensitivity. Subjects were instructed to arrive after a 10–
12 hour fast. For type 2 diabetes, oral anti-diabetic agents were
continued until the day before the study day. For type 1 diabetes,
insulin regimen was changed from long acting to short acting
formulation the day prior to minimize exogenous insulin before
the start of the procedures. Collection for laboratory tests was done
on the morning of the study day. Markers of metabolic regulation,
insulin release and inflammation analyzed included C-peptide,
insulin, free fatty acid, C-reactive protein, adiponectin, RBP-4
(ELISA - ALPCO Diagnostics, USA) and A-FABP (ELISA -
Cayman Chemical, France). Anti-islet antibodies measured
included glutamate decarboxylase (GAD), islet antigen-2 (IA2)
and a competitive insulin antibody assay. DEXA (Hologic 8000)
was performed to evaluate total and regional body fat mass.
HEC was used to assess insulin sensitivity. Dextrose solution
(20%) was administered via intravenous catheter. A second
catheter was inserted retrograde into a vein distal to the first
and then placed into a box heated to 70uC for arterialization of
venous blood. Following collections of baseline samples, a primed-
continuous infusion of regular human insulin (Lilly, Indianapolis)
at 80 mU/m
2/min for 180 minutes was initiated. Blood glucose
samples were obtained and glucose infusion rates adjusted every
five minutes accordingly to maintain a serum glucose concentra-
tion of 90 mg/dl. Glucose disposal rate (GDR) was calculated as
the mean glucose infusion rate during the steady state in the last
40 minutes of the clamp procedure.
Statistical Analysis: All variables were visually and statistically
inspected for distribution to determine appropriate statistical
methods for analysis. Wilcoxon rank sum analysis was used for
two-way comparisons involving continuous variables and Fisher’s
Exact test was used to examine the relationship of categorical
variables. Analyses of variance and tests for linear trends were
done using generalized linear models, designating groups as
categorical or ordinal as appropriate. Linear regression analysis
was used to determine correlation coefficients and to adjust for
potential confounders. p#0.05 was considered statistically signif-
icant. SAS v. 9.2 (Cary, NC) and STATA 9 (College Station, TX)
were used to perform analyses.
Results
The baseline characteristics of all study subjects (n=30) are
presented in Table 1. Two subjects had history of misdiagnosis.
One subject initially presented with hyperglycemia in his early
twenties and with a BMI of 24 kg/m
2. Although he had no history
of ketoacidosis, he was given a diagnosis of type 1 diabetes by his
original physician given his young age and low BMI. The
diagnosis was later corrected to type 2 diabetes by his consulting
physician when it was determined that patient had never
experienced ketoacidosis even after months of insulin omission.
This corrected diagnosis of type 2 diabetes was later confirmed
after being on oral agents for many years prior to entry into the
study with an elevated c-peptide concentration at the time of the
study visit. Another subject was given a diagnosis of type 1 diabetes
Insulin Resistance in Asian American with Diabetes
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28311in her early twenties also because of her young age and a low BMI
(,24 kg/m
2) but had never experienced ketoacidosis nor had a
history of positive anti-islet antibodies. She had an elevated
concentration of c-peptide 5.72 ng/ml with a fasting glucose of
140 mg/dl 6 years post diagnosis at the time of the study visit. Due
to her elevated c-peptide status 6 years after diagnosis, the absence
of DKA, the study investigators consulted with her treating
physician. A switch of therapy from multiple daily injections to
oral agents was made with success, confirming that this subject
indeed had been misdiagnosed. The final study sample consisted of
East AA adults with type 1 diabetes (n=10), type 2 diabetes
(n=9), and the non-diabetic control group (n=11).
Among the three groups, the significant differences included
age, adiponectin, C-peptide, FFA, HbA1c, truncal fat by DEXA,
GDR, CRP, HDL and RBP-4 (Table 1). The combined diabetic
group had a disease duration of 4.663.9 years, were in good
glycemic control (HbA1c=6.961.3%) and did not have a history
of retinopathy, neuropathy or nephropathy. Among those with
Table 1. Baseline characteristics, separated by group.
Type 1 Diabetes
(n=10)
Type 2 Diabetes
(n=9) Controls (n=11)
ANOVA
p value
Wilcoxon
p value
Age (yrs) 25.464.5 31.766.3 26.364.3 0.023 0.0331
Gender male (%) 3(30%) 3(33.3) 5(45.5) 0.74 0.876
Years with DM (yrs) 6.164.0 3.063.4 N/A N/A 0.0764
BMI (kg/m
2)2 3 . 4 61.7 24.563.6 23.363.9 0.650 0.4965
A1C% 6.961.1 7.061.6 5.260.3 0.001 0.1877
Waist Circumference (cm) 76.765.1 84.169.8 79.8610.5 0.200 0.1110
Waist to Hip Ratio 0.8560.02 0.8960.53 0.8960.07 0.150 0.055
Adiponectin (mg/ml) 16.665.6 7.363.5 8.665.1 ,0.0001 0.0003
A-FABP (ng/ml) 12.2631 4 . 3 63 13.166 0.63 0.19
Alb/Creat Ratio (mg/mg) 9.8615.3 11.3611.5 9.268.6 0.438 0.4140
Alkaline Phosphate (IU/l) 52.2616.9 41.268.6 45.469.2 0.157 0.1306
ALT (IU/l) 18.264.2 21.269.2 20.8614.9 0.794 0.6521
AST (IU/l) 21.266.0 20.365.4 20.965.0 0.941 0.8694
Diastolic Pressure (mmHg) 76.869.1 76.967.6 73.968.4 0.660 0.68
Systolic Pressure (mmHg) 117.2617.3 116.2611.6 109.6611.6 0.400 0.90
Cholesterol Total (mg/dl) 164.0643.4 168.1632.7 167.2629.4 0.965 0.3911
Cholesterol LDL (mg/dl) 91.6641.1 103.3624.2 102.5624.6 0.648 0.21
Cholesterol HDL (mg/dl) 60.8610.6 47.8616.1 47.5610.7 0.038 0.045
Triglycerides (mg/dl) 65.8634.7 84.8644.2 91.6656.8 0.440 0.2360
C-peptide (ng/ml) 0.1460.15 2.2961.57 1.3561.21 0.001 0.0003
Creatinine (mg/dl) 0.8260.13 0.7360.14 0.7960.14 0.403 0.2415
CRP (mg/ml) 2.6862.35 1.3161.11 0.81461.02 0.048 0.3074
FFA (mEq/l) 0.5460.19 1.0960.35 0.7760.26 0.0003 0.0373
GDR (mg/min/kg) 7.6262.59 5.4362.7 8.6162.37 0.032 0.0942
GFR (mL/min/1.73 m
2)1 0 1 . 0 614.7 112.2621.1 111.0622.1 0.391 0.1910
HOMA-IR N/A 2.1561.95 1.4360.75 N/A N/A
Leptin (ng/ml) 10.768.4 11.267.4 10.265.8 0.953 0.9674
RBP-4 (mg/ml) 14.8+41 8 . 6 +6 22.2+8 0.02 0.13
Total Body Fat (%) 23.868.4 27.565.4 25.965.4 0.476 0.6830
Total Body Fat (kg) 14.464.7 19.266.3 16.865.7 0.193 0.0942
Total Body Lean (kg) 45.768.7 47.769.7 45.7611.1 0.607 0.4965
Trunk Fat (%) 21.568.0 28.866.7 25.366.2 0.094 0.0942
Trunk Fat (kg) 6.162.1 10.364.3 8.063.7 0.046 0.016
Trunk Lean (kg) 22.463.9 23.964.8 22.465.7 0.691 0.3913
Urea Nitrogen (mg/dl) 14.862.5 12.663.2 14.164.4 0.384 0.1002
GAD Ab+ Subjects* 3(30%) 0% 0% 0.079{ 0.9024
IA2 Ab+ Subjects* 3(20%) 0% 0% 0.23{ 0.88
Data are means 6 SD or n (%). ANOVA performed between all 3 groups: Type 1 Diabetes, Type 2 Diabetes, and Controls.
*Auto-antibody positivity to islet cell antigens was determined by serum concentration.0.1 nU/ml for GAD & IA2, expressed as number of individuals (percent positive).
{Chi-Square tests were performed in these categories.
doi:10.1371/journal.pone.0028311.t001
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glyburide alone, one was on a combination of metformin and
glyburide, one was on insulin and three were diet controlled.
Subjects with type 1 diabetes compared with subjects with type
2 diabetes had significantly lower C-peptide levels (0.1460.15 vs.
2.2961.57 ng/ml, p=0.0003), higher adiponectin (16.665.6 vs.
7.363.5 ug/ml, p=0.0003), higher HDL cholesterol (60.8610.6
vs. 47.8616.1 mg/dl, p=0.045) and only 30% of the subjects with
type 1 diabetes had positive anti-GAD antibody titer (30% vs. 0,
p=0.9024). The outstanding features for subjects with type 2
diabetes, compared with the type 1 diabetes cohort were older age
(31.766.3 vs. 25.464.5 yrs, p=0.0331), higher FFA concentra-
tion (1.0960.35 vs. 0.5460.19 mEq/l, p=0.0373), higher truncal
fat (10.364.3 vs. 6.162.1 kg, p=0.016) and a lower GDR
(5.4362.7 vs. 7.6262.59 mg/min/kg, p=0.0942). In contrast,
BMI, LDL, waist circumference, CRP, leptin, A-FABP and RBP-4
did not differentiate the types of diabetes (Table 1).
According to HEC, the type 2 diabetic group had the lowest
GDR (5.4362.7 mg/min/kg) followed by the type 1 diabetic group
(7.6262.59 mg/min/kg) and healthy controls (8.6162.37 min/kg).
Both type 1 and 2 diabetic groups had well-controlled and com-
parable HbA1c(6.961.1%vs.7.061.6%,p=0.19), minimizing the
impact of glycemic control on measured insulin sensitivity. The type
2 diabetic group was significantly more insulin resistant compared
to the type 1 diabetic and control groups combined (p=0.01). No
significant difference in insulin sensitivity between type 2 diabetic
and control groups was found when using the HOMA-IR model
(p=0.32). As expected, 30% of the subjects in the type 1 diabetic
group had either positive anti-GAD or anti-IA2 antibodies after an
average of 6.164.0 years of diabetes.
In contrast to glucose disposal during HEC, FFA disposal as
reflected by serum FFA concentration plummeted in all three
groups: For controls (0.8760.29 mEq/L at 0 min, 0.176
0.06 mEq/L at 60 min, 0.1260.04 mEq/L at 160 min), for type
1 diabetic group (1.3660.33 mEq/L at 0 min, 0.1560.05 mEq/L
at 60 min, 0.1060.05 mEq/L at 160 min), for type 2 diabetic
group (1.0660.37 mEq/L at 0 min, 0.2060.08 mEq/L at
60 min, 0.1460.13 mEq/L at 160 min).
Visual inspections of the scattered plots outlining the relation-
ships between GDR and the biomarkers traditionally associated
with IR were performed (Fig. 1). We then conducted linear
regression analysis of the relationship between GDR and the
parameters of interest. For all three groups combined, A-FABP
(r=20.54, p=0.002), truncal fat percentage (r=20.52,
p=0.004), total body fat percentage (r=20.47, p=0.01), and
BMI (r=20.36, p=0.051) correlated with GDR in descending
order (Table 2). In contrast, CRP (r=20.31, p=0.09) and RBP-4
(r=20.03, p=0.87) did not correlate with GDR. For the type 1
diabetic group, the only parameter that correlated with GDR was
BMI (r=0.67, p=0.03). In the type 2 diabetic group, only CRP
correlated with GDR (r=20.76, p=0.01). In the control group,
A-FABP (r=20.82, p=0.02) and BMI (r=20.62, p=0.04)
correlated with GDR. Because all the variables tested are related
to degree of adiposity, we adjusted the analysis for BMI, in
addition to age and gender. After adjustment, only A-FABP
correlated strongly to GDR in the entire combined group
(r=20.625, p=0.04) and in controls (r=20.869, p=0.046).
No other variables showed statistical correlation to GDR in the
combined group or in the subgroups.
Discussion
This study provided the first comparative analysis of clinical
phenotype of type 1 and 2 diabetic subjects and healthy controls in
AA. This study confirms that type 1 and type 2 diabetes in AA
share many similar physical characteristics but retain differences
fundamental to their respective pathophysiology. In spite of having
comparable BMIs and waist circumferences, our results from HEC
suggested that type 2 diabetes in AA is more insulin resistant
compared with type 1 diabetes and healthy controls. A-FABP was
identified as having the strongest correlation to IR compared to
conventional markers in AA.
Table 2. Gross and Adjusted Correlations with GDR.
CRP A-FABP RBP-4 TF% TBF%
Rcorr Pcorr Rcorr Pcorr Rcorr Pcorr Rcorr Pcorr Rcorr Pcorr
All 20.36 0.051 20.31 0.09 20.54 0.002 20.03 0.87 20.52 0.004
Type 1 0.67 0.03 20.4 0.24 20.29 0.42 20.2 0.58 20.4 0.25
Type 2 20.54 0.13 20.76 0.01 20.49 0.18 0.01 0.98 20.52 0.15
Controls 20.62 0.04 0.01 0.98 20.82 0.002 20.21 0.5 20.55 0.1
Adjusted Correlations with GDR by age, gender and BMI
All 20.588 0.107 20.625 0.04 20.528 0.637 20.553 0.144 20.452 0.112
Type 1 20.762 0.794 20.763 0.774 20.822 0.266 20.759 0.877 20.76 0.85
Type 2 20.797 0.391 20.745 0.84 20.746 0.805 20.742 0.953 20.756 0.682
Controls 20.707 0.901 20.869 0.046 20.722 0.612 20.779 0.295 20.835 0.13
Data are presented as Pearson correlation coefficient (R), and corresponding p value. Variables presented: BMI, C-Reactive Protein (CRP), Adipocyte Fatty Acid-Binding
Protein (A-FABP), Retinol Binding Protein-4 (RBP-4), Total Body Fat (TBF%) by DEXA, and Truncal Fat percentage (TF%). Type 1 diabetes group (Type 1), Type 2 diabetes
group (Type 2). Adjusted correlations with GDR by age, gender and BMI.
doi:10.1371/journal.pone.0028311.t002
Figure 1. Relationship between glucose infusion rate (GDR) and various biomarkers for insulin resistance. Relationship between GDR
and Adiponectin, Free fatty acid (FFA), Waist circumference, A-FABP, C-reactive protein (CRP), Total Body Fat (TBF) by DEXA, BMI, and Retinol Binding
Protein-4 (RBP-4). Circles=Type 1 group; Squares=Type 2 diabetes group; Triangles=Control group.
doi:10.1371/journal.pone.0028311.g001
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misdiagnosis of diabetes type in AA, two individuals with type 1
diabetes in our study were initially misdiagnosed by their
physicians, illustrating the diagnostic challenge in young AA.
Markers of autoimmunity to islet cells may not be helpful as studies
in Asians found that less than half have evidence of auto-
antibodies against islet antigens at diagnosis [4], which is usually
positive in 90% in Caucasian patients at time of diagnosis [15].
Commonly used clinical measurements such as BMI and other
inflammatory biomarkers did not differentiate types of diabetes in
AA which are different from studies involving Caucasian and other
minority populations that show BMI and CRP are reliable
predictors of type 2 diabetes [16]. Clinical diagnosis based on
status of insulin dependence, history of ketoacidosis aided by
unequivocal c-peptide concentration often guides clinical decision
in many ambiguous cases. In addition, parameters such as
adiponectin, HDL, FFA concentrations, truncal fat and GDR,
not only differentiated type 2 from type 1 diabetes, but also
suggested a mechanistic link to visceral adiposity. The elevated
levels of adiponectin in AA with type 1 diabetes are interesting and
clearly differentiated them from AA with type 2 diabetes. Further
studies in Asian or AA populations are needed to confirm whether
this significant elevation of adiponectin in AA with type 1 diabetes
is related to young age, good glycemic control and the low
prevalence of cardiovascular complications in East AA.
An earlier study found that healthy non-obese AA matched for
body fat percentage are more insulin resistant than their
Caucasian counterparts using the hyperglycemic clamp method
[17]. Our study using HEC extended the finding within the East
AA ethnic group that IR is a pathophysiological component of
type 2 diabetes even when their weight is within normal range.
Future studies are needed to determine whether targeting insulin
resistance independent of weight loss is important in the treatment
of type 2 diabetes in this population. Furthermore, this study
provides new data to document, using HEC and supported by
high HDL and adiponectin, that AA with type 1 diabetes do not
have significant IR if glucose levels are well controlled. The
positive correlation between GDR and BMI in the type 1 diabetic
group (Figure 1) is worth noting. Although the mechanism is
unclear, the correlation could be related to the degree of glycemic
control in type 1 diabetes as optimal glucose control improves
insulin sensitivity but may lead to weight gain.
Unlike the variable glucose disposal rates among the three
groups, a sharp decline in FAA concentration was universal during
HEC in all three groups. Insulin is known to promote the synthesis
of fatty acids in the liver and reduce the breakdown of fat in the
adipose tissue by inhibiting hormone sensitive lipase activities.
Despite the known fact that FAA are elevated in type 2 diabetes,
the high insulin concentration used during HEC obliterated the
differences in FAA but not glucose disposal among the three
groups, raising the likely possibility that that regional insulin
resistance towards glucose metabolism not fat metabolism, may
underlie the pathophysiology of IR in AA.
Using HEC, we have documented that A-FABP is closely
associated with IR but mostly in the control group and not so tightly
once diabetes has occurred. This supports that IR has a greater
effect on FABP levels in non-diabetic controls than in the diabetic
state and suggests that other factors besides IR regulates FABP once
diabetes has developed. The strong correlation of A-FABP to IR,
independent of BMI, may have a clinical relevance to screening for
risks of diabetes in AA because generalized obesity is not common
and a blood test is simple for assessing IR. Furthermore, the existing
correlation independent of BMI also suggests that A-FABP levels
may not be regulated by pathways related to obesity. A-FABP, a
cytoplasmic protein abundantly present in serum and expressed
only in adipocytes and macrophages, avidly binds to intracellular
fatty acids [18]. Their functions include the transport of FFA to
cytoplasmic compartmentsinadditionto regulatinggene expression
relating to lipid metabolism and inflammatory cytokines. FABP has
been shown to be regulated by glucocorticoids, PPAR- c agonists,
fatty acids and insulin [19], which may provide the mechanic
framework for the link to insulin sensitivity. In a longitudinal studies
from Hong Kong, serum A-FABP was associated with glucose
intolerance and predicted the development of type 2 diabetes in a
Chinese cohort followed over ten years [14], pointing to its potential
as a prognostic tool. Similarly, A-FABP was associated with
metabolic syndrome independent of adiposity and IR, expanding
its role as a predictor for cardiovascular diseases [13]. However, our
results, although limited by the small sample size, raises the
hypothesis that diagnostics targeting A-FABP may only be effective
before the onset of diabetes.
In contrast to earlier studies, we did not find RBP-4 to be
correlated to GDR. The original publication linking RBP-4 to
IR was done in Caucasians only [11]. Our study also differed
from the conclusion of a study from China [12] showing a
correlation of RBP-4 to IR, in that we studied AA and used a
different assay. The major weakness of the study is the small
sample size which limited our ability to run multiple adjustments
in the model regarding smoking, family history and physical
activities. It also did not allow a comprehensive matching
between the groups. Stopping oral anti-diabetic agents prior to
the entry of the study would have been an ideal way to study IR
in the type 2 group. However, the internal review board
discourages such practice due to putting patients at risk for
adverse events even if the risk is minimal. To address the
potential effect of oral agents, we have specifically excluded
individuals on thiazolidinediones, which are known to have the
most impact on insulin resistance, to minimize the impact of oral
agents on measured insulin sensitivity. In addition to determine
IR, assessing the b-cell function in non-obese individuals with
type 2 diabetes is very important, however, beyond the scope of
this pilot study. Therefore a separate study will be needed to fully
examine the interaction between insulin secretion and insulin
resistance. It is likely that our result only applies to young East
AA populations. South Asian Americans are generally more
insulin resistant [20], have elevated CRP concentrations and
more cardiovascular diseases despite sharing the similar feature
of low BMI with East AA. The strength of our study is the use of
HEC as the definitive procedure for the assessment of insulin
sensitivity, enabling the direct comparison of emerging biomark-
ers with conventional markers for IR. We have also included the
assessment of IR in type 1 diabetes in East AA subjects, which
has not been reported in previous literature.
In summary, our pilot study confirmed that insulin resistance is
a pathophysiologic feature of type 2 diabetes in AA despite the
association with normal BMI. Biomarkers, such as adiponectin,
that reflect visceral adiposity maybe more sensitive than
conventional anthropometric markers in differentiating type 1
from type 2 diabetes in AA. Lastly, A-FABP concentration,
seemingly unaffected by adiposity, emerged as an interesting
biomarker for IR and may be useful for identifying non-diabetic
AA with IR.
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